Skip to content

PTC Therapeutics PTCT Payments to Acquire Intangible Assets

Payments to Acquire Intangible Assets at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
Biogen logo
BiogenBIIB
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$6.55B+40.3%
Enterprise value$6.11B+77.3%
P/E
P/S7.9×+5.3×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's payments to acquire intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTC Therapeutics's payments to acquire intangible assets?
PTC Therapeutics (PTCT) reported payments to acquire intangible assets of $156K in Q1 2026.
How has PTC Therapeutics's payments to acquire intangible assets changed year-over-year?
PTC Therapeutics's payments to acquire intangible assets decreased by 80.7% year-over-year, from $808K to $156K.
What is the long-term trend for PTC Therapeutics's payments to acquire intangible assets?
Over 4 years (2021 to 2025), PTC Therapeutics's payments to acquire intangible assets has grown at a 50.3% compound annual growth rate (CAGR), from $57.12M to $291.15M.